



Research Ethics Committee

Crta. De Canyet, s/n - 08916 Badalona Tel. +34 93 497 89 56 Email: ceic.germanstrias@gencat.cat Website: www.ceicgermanstrias.cat

HUGTIP REC SUBMISSION REQUIREMENTS: SUBSTANTIAL AMENDMENTS IN PART I AND/OR PART II (CLINICAL TRIALS WITH MEDICINAL PRODUCTS)

You shall submit the online assessment application via the <u>Clinical Trials with Medicinal Products Portal of the AEMPS</u> including the following documents:

- 1. Cover letter.
- 2. Application form for substantial amendments.
- 3. Summary and justification of changes.
- 4. Comparative table of changes versus previous version.
- 5. New version of modified documents.
- 6. New documents.
- 7. Documents supporting the changes (if applicable).
- 8. Consequences of the modification, which must include:
 - An updated overall assessment of the risk-benefit ratio.
 - Possible consequences for the subjects included in the trial.
 - Possible repercussions on the assessment of the results.
- 9. Invoice request form / Proof of payment of fee to the REC (when applicable).
- >> If the substantial amendment only involves an **addition of a new site, change of Principal Investigator** and/or **change of sponsor**, you shall send the following documentation:
- 1. Cover letter.
- 2. Application form for substantial amendments.
- 3. Proof of insurance cover or updated financial guarantee.
- 4. Invoice request form / Proof of payment of fee to the REC (when applicable).

And, in addition, the following specific documents:

| ADDITION OF NEW SITES | CHANGE OF P. INVESTIGATOR | CHANGE OF SPONSOR |
|---|---|--|
| 5. Updated financial report (if applicable). 6. Updated document on the suitability of the investigators. 7. Documents that must be submitted to each new site: Summary CV of the Principal Investigator Suitability of the facilities document | 5. Updated document on the suitability of the investigators.6. Summary CV of the Principal Investigator. | 5. Document issued by the sponsor delegating functions and responsibilities. |

If you need more information about the practical aspects involved in the implementation of Royal Decree 1090/2015 you can visit the website of the Spanish Agency of Medicines and Medical Devices